Back to Authors

Thibodeau, Stephen N.

https://orcid.org/0000-0003-0078-8558

Mayo Clinic

Mayo Clinic

Citations 169

Overall survival result and outcomes by KRAS, BRAF, andDNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147.
Yoon, Harry H. , Mahoney, Michelle R., Nelson, Garth D. , Thibodeau, Stephen N. , Goldberg, Richard M. , Sinicrope, Frank A. , Sargent, Daniel J. , Alberts, Steven R.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3525-3525

10.1200/jco.2014.32.15_suppl.3525 Get It

Association of the HOXB13 G84E mutation with increased risk for prostate cancer and other malignancies.
Beebe‐Dimmer, Jennifer , Isaacs, William B. , Thibodeau, Stephen N. , Yee, Cecilia, Ewing, Charles M., Okoth, Linda A. , Cooney, Kathleen A.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 1558-1558

10.1200/jco.2014.32.15_suppl.1558 Get It

Racial differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147 [Alliance]).
Yoon, Harry H. , Goldberg, Richard M. , Thibodeau, Stephen N. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. , Sinicrope, Frank A.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3536-3536

10.1200/jco.2014.32.15_suppl.3536 Get It

Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)].
Thibodeau, Stephen N. , Goldberg, Richard M. , Sinicrope, Frank A. , Shi, Qian , Sargent, Daniel J. , Alberts, Steven R.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3512-3512

10.1200/jco.2014.32.15_suppl.3512 Get It

Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database.
Thibodeau, Stephen N. , Gallinger, Steven , Monges, Geneviève, Pogue–Geile, Katherine L. , Roth, Arnaud, Pavey, Emily S., Kim, George P., Group, ACCENT Collaborative, Sargent, Daniel J. , Shi, Qian , Yothers, Greg , Tejpar, Sabine , Bertagnolli, Monica M. , André, Thierry , Labianca, Roberto , Hamilton, Stanley R. , Paik, Soonmyung , Klingbiel, Dirk , Sinicrope, Frank A. , Group, ACCENT Collaborative

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3507-3507

10.1200/jco.2014.32.15_suppl.3507 Get It

Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study
Adams, Charleen D. , Richmond, Rebecca C. , Ferreira, Diana L. Santos , Spiller, Wes , Tan, Vanessa Y. , Würtz, Peter , Donovan, Jenny , Hamdy, Freddie C. , Neal, David E. , Lane, J. Athene , Smith, George Davey , Relton, Caroline L. , Eeles, Rosalind A. , Haiman, Christopher A. , Schumacher, Fredrick R. , Olama, Ali Amin Al , Benlloch, Sara, Muir, Kenneth , Berndt, Sonja I., Conti, David V. , Gapstur, Susan M. , Stevens, Victoria L. , Batra, Jyotsna , Grönberg, Henrik , Pashayan, Nora , Schleutker, Johanna , West, Catharine , Mucci, Lorelei A. , Koutros, Stella , Sørensen, Karina D. , Mæhle, Lovise, Travis, Ruth C. , Rosenstein, Barry S. , Lu, Yong‐Jie , Kibel, Adam S. , Vega, Ana , Stanford, Janet L. , Nordestgaard, Børge G. , Maier, Christiane, Kim, Jeri , John, Esther M. , Teixeira, Manuel R. , Newcomb, Lisa F., Lessel, Davor , Kaneva, Radka , Usmani, Nawaid , Claessens, Frank , Townsend, Paul A. , Dominguez, Manuela Gago, Roobol, Monique J. , Ménégaux, F. , Pandha, Hardev , Thibodeau, Stephen N. , Martin, Richard M. , Teixeira, Manuel R , Vega, Ana , Eeles, Rosalind A , John, Esther M , Donovan, Jenny L , Muir, Kenneth , Schleutker, Johanna , Travis, Ruth C , Pashayan, Nora , Lessel, Davor , Koutros, Stella , Martin, Richard M , Conti, David V , Batra, Jyotsna , Davey Smith, George , Zheng, Jie , Kote‐Jarai, Zsofia , Berndt, Sonja I. , Wiklund, Fredrik E. , Chanock, Stephen Jacob , Tangen, Catherine M. , Clements, Judith A. , Albanes, Demetrius , Wolk, Alicja , Cancel‐Tassin, Géraldine , Hamilton, Robert J , Ingles, Sue A. , Giles, Graham G. , Kogevinas, Manolis , Penney, Kathryn , Park, Jong Y. , Cybulski, Cezary , Brenner, Hermann , Neuhausen, Susan L. , Ruyck, Kim De , Razack, Azad Hassan Abdul , Khaw, Kay‐Tee , Cannon‐Albright, Lisa , Claessens, Frank

Cancer Epidemiology, Biomarkers & Prevention | October 23, 2018 | Volume: 28 | Issue: 1 | Pages: 208-216

10.1158/1055-9965.epi-18-0079 Get It

Abstract Background: Whether associations between circulating metabolites and prostate cancer are causal is unknown. We report on the largest study of metabolites and prostate cancer (2,291 cases and 2,661 controls) and appraise causality for a subset of the prostate cancer–metabolite associations using two-sample Mendelian randomization (MR). Methods: The case–control portion of the study was conducted in nine UK centers with men ages 50–69 years who underwent prostate-specific antigen screening for prostate cancer within the Prostate Testing for Cancer and Treatment (ProtecT) trial. Two data sources were used to appraise causality: a genome-wide association study (GWAS) of metabolites in 24,925 participants and a GWAS of prostate cancer in 44,825 cases and 27,904 controls within the Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. Results: Thirty-five metabolites were strongly associated with prostate cancer (P < 0.0014, multiple-testing threshold). These fell into four classes: (i) lipids and lipoprotein subclass characteristics (total cholesterol and ratios, cholesterol esters and ratios, free cholesterol and ratios, phospholipids and ratios, and triglyceride ratios); (ii) fatty acids and ratios; (iii) amino acids; (iv) and fluid balance. Fourteen top metabolites were proxied by genetic variables, but MR indicated these were not causal. Conclusions: We identified 35 circulating metabolites associated with prostate cancer presence, but found no evidence of causality for those 14 testable with MR. Thus, the 14 MR-tested metabolites are unlikely to be mechanistically important in prostate cancer risk. Impact: The metabolome provides a promising set of biomarkers that may aid prostate cancer classification.
Association of tumor infiltrating lymphocytes (TILs) with molecular subtype and prognosis in stage III colon cancers (CC) from a FOLFOX-based adjuvant chemotherapy trial.
Smyrk, Thomas C. , Foster, Nathan R. , Meyers, Jeffrey P., Thibodeau, Stephen N. , Goldberg, Richard M. , Sinicrope, Frank A. , Shi, Qian , Sargent, Daniel J. , Alberts, Steven R.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3518-3518

10.1200/jco.2016.34.15_suppl.3518 Get It

Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials.
Allegra, Carmen J. , Smyrk, Thomas C. , Thibodeau, Stephen N. , Goldberg, Richard M. , Meyers, Jeffrey P., Sinicrope, Frank A. , Shi, Qian , Yothers, Greg , Sargent, Daniel J. , Alberts, Steven R.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3600-3600

10.1200/jco.2016.34.15_suppl.3600 Get It

Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance).
Hua, Xinwei , Banbury, Barbara L. , Phipps, Amanda I. , Kocarnik, Jonathan, Harrison, Tabitha A. , Thibodeau, Stephen N. , Chan, Emily , Goldberg, Richard M. , Kahlenberg, Morton S., Nair, Suresh , Shields, Anthony F. , Jahagirdar, Balkrishna, Peters, Ulrike , Harrison, Tabitha A , Newcomb, Polly A. , Sun, Wei , Shi, Qian , Sinicrope, Frank A. , Gill, Sharlene , Alberts, Steven R. , Chan, Andrew T.

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 3604-3604

10.1200/jco.2017.35.15_suppl.3604 Get It

3604 Background: Limited research has investigated the role of variation in the host genome as a determinant of colon carcinoma (CC) outcomes, including toxicity due to therapeutic agents. We examined the relationship between germline genetic factors and treatment-associated serious adverse events (SAEs) in a population of CC patients in which treatment was standardized and follow-up for outcomes was uniformly conducted. Methods: Using existing biospecimens from CC patients with resected stage III disease in a phase III randomized trial of FOLFOX adjuvant chemotherapy with and without cetuximab (NCCTG N0147), genome-wide genotyping arrays were conducted for 2200 patients for a total of ~20 million single nucleotide polymorphisms (SNPs). Using logistic regression models we assessed SNP-specific associations with SAEs, utilizing a discovery-based approach to search the genome in an unbiased manner. Detailed information on SAEs was collected using the Common Toxicity Criteria for Adverse Events (CTCAE, v3.0). Analyses evaluating associations with specific classes of common grade ≥3 SAEs were performed, including gastrointestinal toxicities, neutropenia, and paresthesias. A threshold of P < 5x10-8was used to denote genome-wide significance. Results: Among patients who received FOLFOX, several SNPs on chr 15 near the ANP32A gene and on chr 2 near the CD207 gene were statistically significantly associated with grade ≥3 neuropathy. The strongest SNP-specific associations in these regions were in the range of odds ratio (OR) = 1.3, P = 2.8×10−10 and OR = 1.5, P = 2.7×10−10, respectively. Conclusions: Findings from this genome-wide analysis demonstrate the potential importance of germline genetic variation in influencing CC patients’ experience of specific toxicities to FOLFOX regimens. These results highlight two genomic regions of potential interest for understanding the biological mechanism for such toxicities, although further evaluation and replication is needed. Support: U10CA180821, U10CA180882, U10CA180820, U10CA180863, U10CA180888, CCSRI 021039, R01CA176272, Eli Lilly & Co, Pfizer, Sanofi. Clinical trial information: NCT00079274 .
Abstract 5268: Interactions between genetic predictors of gene expression and dietary factors associated with risk of colorectal cancer
Petersen, Paneen S., Berndt, Sonja I. , Brenner, Hermann , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gallinger, Steven , Harrison, Tabitha A. , Hoffmeister, Michael , Jenkins, Mark A. , Joshi, Amit D. , Küry, Sébastien , Lindor, Noralane M. , Slattery, Martha L. , Thibodeau, Stephen N. , Peters, Ulrike , CCFR, GECCO, Hoffmeister, Michael , Jenkins, Mark A , Harrison, Tabitha A , Kury, Sebastien , Brenner, Hermann , Su, Yu-Ru , Bien, Stephanie A. , Casey, Graham , Chan, Andrew T. , Haile, Robert W. , Marchand, Loı̈c Le , Lin, Yi , Newcomb, Polly A. , Potter, John D. , Schoen, Robert E. , White, Emily E. , CCFR, GECCO

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 5268-5268

10.1158/1538-7445.am2018-5268 Get It

Abstract Genome-wide association studies of colorectal cancer (CRC) have identified over 50 susceptibility loci. These variants represent only a small fraction of total heritability for CRC. Gene-environment (GxE) interaction studies may help identify novel loci and biological interactions that give insight to the pathogenesis of CRC. Previous genome-wide GxE studies with dietary factors have identified interactions between loci and processed meat consumption and alcohol; however, limited statistical power remains a primary concern. Set-based SNP testing has the potential to increase statistical power to detect GxE interactions by aggregating functionally relevant SNPs. In this large pooled analysis using 14 case-control and nested case-control studies, we incorporated functional information from the transcriptome prediction tool, PrediXcan, into a novel set-based approach for testing GxE interactions. We used variant weights from the PrediXcan models of tissue-specific gene expression in the transverse colon as a priori variant information for a set-based GxE approach. We restricted our analysis to variants in the PrediXcan transverse colon gene models (n = 4,842). This discovery phase included 10,360 CRC and advanced adenoma cases, and 11,183 controls of European ancestry from the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) and the Colon Cancer Family Registry. All 14 studies were analyzed together in a pooled data set using the Mixed Effects Score Tests for interactions. We tested for gene interactions with sex- and study- specific quartiles of dietary intake of red meat (servings/day), processed meat (servings/day), vegetables (servings/day), fruits (servings/day), and fiber (g/day). We detected two genes with suggestive interactions (false discovery rate (FDR) &lt; 0.2) with intake of red meat and risk of CRC: Superoxide Dismutase 2 (SOD2) and Ubiquitin Conjugating Enzyme E2 H (UBE2H). No interactions at FDR &lt; 0.2 were observed for processed meat, vegetables, fruits, or fiber. The SOD2 gene, which encodes an enzyme important in apoptotic signaling and clearing of reactive oxygen species, may regulate response to colonic exposure to heme iron or increased bile acid from high-fat content in red meat. UBE2H is part of the ubiquitin-proteasome system that has a role in Wnt signaling, which can be mediated by heme iron in red meat and is commonly found dysregulated in cancer. These findings highlight the efficacy of integrating functional information and set-based testing for novel discovery of genes interacting with known dietary risk factors of CRC. We plan to replicate these findings in additional studies. Citation Format: Paneen S. Petersen, Yu-Ru Su, Sonja I. Berndt, Stephanie A. Bien, Hermann Brenner, Graham Casey, Andrew T. Chan, Jenny Chang-Claude, Jane C. Figueiredo, Steven J. Gallinger, Robert W. Haile, Tabitha A. Harrison, Michael Hoffmeister, Mark A. Jenkins, Amit D. Joshi, Sébastien Küry, Loic Le Marchand, Yi Lin, Noralane M. Lindor, Polly A. Newcomb, John D. Potter, Robert Schoen, Martha L. Slattery, Stephen N. Thibodeau, Emily White, Li Hsu, Ulrike Peters, CCFR, GECCO. Interactions between genetic predictors of gene expression and dietary factors associated with risk of colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5268.